I am a Patent Attorney with a decade of experience who works with innovators to obtain robust and enforceable patents with commercially relevant claims.
Alexander Chatterley is an associate and Registered Patent Attorney in Foley Hoag's Intellectual Property Department. He works with clients to obtain U.S. and foreign patents related to pharmaceuticals, biotechnology, and materials technology. He also has experience in assisting clients with the preparation of licensing agreements and the monetization of royalty streams.
Prior to his career at Foley Hoag, Alex was involved in a multitude number of drug discovery efforts, most recently as a post-doctoral research associate under Professor Peter Wipf at the University of Pittsburgh. Prior to this posting, Alex was employed as a Senior Research Scientist with Albany Molecular Research Inc. at Erl Wood Manor, which at the time was Eli Lilly’s premier research facility in Europe.
In his graduate work, Alex developed new routes towards the Coleophomone group of natural products under the tutelage of Professor Ray Jones of Loughborough University and Dr. Martin Owton of Eli Lilly.
Nottingham Trent University, Master of Chemistry, 2010, Top of Class
Bar and Court Admissions
BAR ADMISSIONS
Massachusetts
U.S. Patent & Trademark Office (Agency)
Experience
LEGAL EXPERIENCE
Served as patent prosecution counsel for a variety of large and small pharmaceutical companies, GreenTech companies, venture-backed research institutions, and universities. A list of representative patents obtained is shown below:
Small molecule pharmaceuticals:
Use of Inhibitors of Bruton’s Tyrosine Kinase (BTK) to (e.g., ibrutinib) (US 10,793,535; AbbVie/Pharmacyclics)
Bicyclic heterocyclyl derivatives as IRAK4 inhibitors to (e.g., emavusertib) (US 10,995,100; Curis, Inc./Aurigene Oncology)
FAP-targeted radiopharmaceuticals and imaging agents, and uses related thereto (US 11,707,539; Tufts University)
Small Molecule Polymorphs:
Crystal forms of crenolanib and methods of use thereof (US 12,486,256; Arog Pharmaceuticals, Inc.)
Crystal forms of immunomodulators (US 11,040,948; Curis, Inc./Aurigene Oncology)
Antibody-drug conjugates:
Compounds comprising self-immolative group (US 9,991,057; Ligachem Biosciences Inc.)
Antibody-drug conjugates comprising branched linkers and methods related thereto (US 11,173,214; Ligachem Biosciences Inc.)
Lipid based drug delivery
Lipid-like nanocomplexes and uses thereof (US 12,133,855; Tufts University)
Carbon capture
Alkaline cation enrichment and water electrolysis to provide CO2 mineralization and global-scale carbon management (US 12,161,972; University of California)
Oxygen-selective anodes (US 12,247,303; University of California)
Seawater electrolysis enables Mg(OH)2 production and CO2 mineralization (US 12,359,323; University of California)
Works closely with litigation counsel on technical and patent prosecution matters in high-stakes patent disputes (e.g., Enanta Pharmaceuticals, Inc. v. Pfizer Inc.).
Advises on IP licensing matters, including the evaluation of patent portfolio scope, claim coverage, and freedom-to-operate considerations in connection with licensing negotiations.
Partners with capital markets teams on regulatory filings (e.g., S-1 filings), contributing prosecution expertise to intellectual property descriptions, risk factor analysis, and portfolio diligence.
PROFESSIONAL EXPERIENCE
University of Pittsburgh, Post-Doctoral Research Associate with Professor Peter Wipf (2015-2017)
Albany Molecular Research Inc., Senior Research Scientist (2014-2015)
Other Publications
U.S. 11,247,985 - Phenyl indole allosteric inhibitors of P97 ATPase
Jones, R.C.F., Chatterley, A., et al., Isoxazole to Oxazole: A Mild and Unexpected Transformation. Chem. Commun., 2015, 51, 1112–1115
Honors & Involvement
HONORS
Best Lawyers: Ones to Watch
Patent Law (2024-2027)
Life Sciences Practice (2026, 2027)
Intellectual Property Law (2026, 2027)
World Intellectual Property Review, WIPR Leaders (2024)
We use cookies to enhance user experience, improve functionality and performance, and for analysis of website traffic. By clicking “accept”, you agree to the use of cookies. For more information about our cookie policy and the information we collect, please review our Privacy Statement.
Foley Hoag
Email Disclaimer
Transmitting information to us by e-mail unilaterally does not establish an attorney-client relationship or impose an obligation on either the law firm or even the receiving lawyer to keep the transmitted information confidential. By clicking "OK," you acknowledge that we have no obligation to maintain the confidentiality of any information you submit to us unless we already represent you or unless we have agreed to receive limited confidential material/information from you as a prospective client. Thus, if you are not a client or someone we have agreed to consider as a prospective client, information you submit to us by e-mail may be disclosed to others or used against you.
If you would like to discuss becoming a client, please contact one of our attorneys to arrange for a meeting or telephone conference. If you wish to disclose confidential information to a lawyer in the firm before an attorney-client relationship is established, the protections that the law firm will provide to such information from a prospective client should be discussed before such information is submitted. Thank you for your interest in Foley Hoag.
